Epstein-Barr virus (EBV) 1 is a herpes virus with a very narrow tropism in that it can only infect humans and primates, and only the B lymphocytes of these susceptible species (1). The virus will activate the host cell from a state of rest to a high rate of immunoglobulin (Ig) secretion (2) and, moreover, a proportion of the infected B cells have been shown to proliferate indefinitely in vitro (3). This virus is the causative agent in infectious mononucleosis (4), and it has strong association with certain human B lymphocyte tumors (1).
on a Ficoll gradient, and the layer not binding SRBC was recovered. These cells (B 1) contained <5% SRBC binding lymphocytes as judged by rerosetting, but contained >50% monocytes as judged by acridin orange staining (7) .
The extensively purified B cell preparation (B2) was obtained by first clearing the Ficollseparated cells from monocytes by exposing them to iron powder, followed by magnet treatment. Then the cells were passed through a nylon wool column and the retained cells were eluted by fetal bovine serum (FBS) at 37°C. The eluted fraction was rosetted with SRBC and spun over Ficoll-Isopaque to remove any remaining SRBC-binding T cells. This yielded a cell suspension with <1% SRBC binding cells and no proliferative response to T cell mitogens (8) .
Tissue Culture. The cells were cultivated either in 2-ml round-bottomed tubes or 25-ml flasks in 5% CO2 in air. The RPMI 1640 medium was supplemented with either 10% heat-inactivated FBS or human AB serum and antibiotics (penicillin and gentamycin).
Viral Exposure of Cells. Two preparations of EBV were used, i.e., the transforming virus obtained from the supernate of the B95-8 marmoset line (9) and the nontransforming variant from the supernate of the P3HR-1 Burkitt-derived line (10) . Both virus-containing supernates were filtered (0.45-/1 pore size) before use.
Virus exposure was performed by suspending the cell pellets in virus-containing supernate and incubating this mixture for 60 min at 37°C at a concentration of 106 cells/ml. After this incubation, the cells were washed twice and cultivated in serum-supplemented RPMI 1640. When exposed to the T cell-dependent activator pokeweed mitogen (PWM) (Techtum, Ume~, Sweden), the cells were in continuous contact with the agent at a concentration of 20 ~g/ml. 
Measurement and

Demonstration of EBV-determined Nuclear Antigen (EBNA ).
Methanol-acetone-fixed smears of cells were prepared and stained by anti-complement immunofluorescence (11) after exposure to an anti-EBNA-positive serum.
Protein-A Plaque Assay. This was performed as we have described previously (5) . Protein-Acoupled erythrocytes were obtained by exposing one part washed and packed SRBC to one part staphylococcal protein A (Pharmaeia Fine Chemicals, Uppsala, Sweden) at a concentration of 0.5 mg/ml in i0 parts CrCI~. Rabbit anti-human/l, y, and c~ antisera (Dako Ig, Copenhagen, Denmark), diluted 1:50, were used as developing sera. Guinea pig serum absorbed with equal volumes of packed SRBC for 1 h at 4°C was the source of complement. Plaque-forming cells (PFC) are expressed as PFC/10 n cells initially cultured.
Results
Relationship between Ig Production, De Novo DNA Synthesis, and Intracellular Presence of Viral Antigens in B Lymphocytes Exposed to EBV. Highly purified B cells (B2) were exposed to dilutions of B95-8 supernate. In such treated cells, the proportion of EBNA-positive cells was assayed after 2 and 6 d, respectively, and the number of IgM-producing B cells was measured, as well as the level of DNA synthesis after 7 d of culture (Fig. 1 ). There is a linear decrease of all these parameters as a function of virus dilution.
In Fig. 2 , it is evident that the induction of IgM-secreting cells falls linearly as a function of virus dilution in both purified (B 1) and nonpurified (B plus T) lymphocyte preparations. The purified B cells, however, yield higher peak values and support a response with more dilute virus preparations. exposure of highly purified B lymphocytes (B2) in the presence of Ara-C (12). Table  I shows that cells that have been in contact with EBV (B95-8) for 7 d, but were in the presence of Ara-C for the last 36 h, show a marked reduction of DNA synthesis and also generate fewer Ig-secreting cells than the controls without Ara-C (Table I) . Ara-C was also added 36 h after virus exposure and the EBNA staining and determination of Ig-secreting cells was performed 36 h later, i.e., 3 d after starting the culture. No Igsecreting cells were discernable in this experiment, although 13% of the cells stained for EBNA, which would indicate the proportion of cells infectible by EBV in this preparation. In other preparations, where DNA synthesis was inhibited by Ara-C at this early stage, up to 30% of the purified B cells have been infectible by EBV as judged by EBNA positivity. An alternative approach for establishing the requirement for B cell transformation in the maturation leading to active Ig secretion was to expose the cells to the nontransforming variant of EBV, i.e., P3HR1. This virus preparation failed (Table  II) to induce Ig secretion, as well as DNA synthesis in human B cells, but it could specifically block these actions from subsequently added transforming EBV (B95-8). This effect of P3HR 1 is not the result of a toxic or cytostatic action of the virus upon B cells in general, because such treated cells can still be activated by PWM (Table   II) . and incubating for an additional 12 h. 20 #g Ara-C was added 36 h before harvest at day 7. § Cells were exposed to the supernate of B95-8 line (106/ml) for 1 h. Thereafter they were washed and cultivated in RPMI 1640 with 10% FBS in round tubes.
Role of De Novo DNA Synthesis and Transformation in the EBV-dependent Induction of Ig
Possible Role of T Cells in Stopping the Development of Ig-secreting Cells in Short-Term Culture Stimulated by EB V.
In comparing the EBV responsiveness of purified (B 1) vs.
nonpurified (B plus "1") B cells, we also studied the kinetics of response measured by the development of IgM-secreting cells. T cell-deprived preparations showed a continuous increase of cells producing IgM, as well as a high proportion of EBNA-positive * Virus preparations were added by suspending 106 cells in 1 ml of virus supernates for 60 min at 37°C. After washes, the ceils were incubated in RPMI 1640 with 10% human AB serum. 20/~g/ml of PWM added at day 0. § Sequential addition of virus was done by first exposing the cells to one virus as described above, followed by washes, and then to the second virus supernate, followed by washes, after which the cells were put in culture.
cells as late as 14 d after initiating the culture (Fig. 3) , at a time when cell mixtures containing T cells showed very few Ig-secreting cells, as well as a low content of EBNA-positive cells.
Discussion
We have determined by these experiments that the EBV-induced activation of human B lymphocytes is a dose-dependent, one-hit phenomenon, and that the maturational step involved in the process of activation requires de novo DNA synthesis.
Although EBV receptors appear to be present on virtually all B cells, as well as some null cells (13, 14) , only a fraction of these B cells (10-30%) appears in our experiments to be infectible by the virus, as judged by the appearance of EBNA before DNA synthesis is initiated. We can say this provided that the concentration of virus is not the limiting factor. This does not appear to be the case, as we see a plateau effect with the lower viral dilutions (Fig. 2) . However, using extensively concentrated virus, larger proportions of B cells (___90%) have on occasion been infected (15). We do not know what characterizes the B cells to which the virus can gain intracellular access, nor do we know what signifies the smaller fraction of the B cells (1-3%) that is driven to Ig secretion by the virus. We can perform the latter calculation because we know from our previous work that all Ig-producing cells in a cell culture exposed to EBV contain the EBNA antigen (2) .
It is well established that the EBV infection proceeds via the induction of EBNA (10 h), and later, (40 h) of DNA synthesis (16) .
Differentiation from a rest state to active Ig synthesis in a B cell after EBV infection appears to be dependent on de novo DNA synthesis. This is true for all three major isotypes ( Table I) sensitive to the action of Ara-C than to IgG and IgA. This is in agreement with previously published information (17) , which indicates that an immunological switch from IgM to IgG is strictly dependent of DNA synthesis, whereas the path from rest to active IgM secretion seems to be less so. In this system, we know that the virus is incorporated in cellular DNA and that viral proteins are synthesized, although DNA synthesis is blocked, but that a high rate of Ig secretion is not initiated under those conditions. Recently, an agent has been described that can induce mainly IgM synthesis in human B cells without the need for de novo DNA synthesis (18) . EBV and formalin-killed Salmonella paratyphi thus differ in this regard.
Nontransforming EBV, i.e., P3HR1, does not induce DNA synthesis or Ig formation in human B cells (Table II) . Furthermore, P3HR1 will specifically block the Iginducing action of subsequently added transforming B95-8. This may suggest that the viruses compete for similar membrane and/or intraeellular sites in the same cells. Because the Ig-inducing action of PWM is not blocked, one must conclude that PWM either activates different subsets of B cells or uses different pathways of activation (19) .
Finally, T cell-deprived B cell suspensions do not clear themselves of the EBNApositive cells, as the T cell-containing suspensions do (Fig. 3) . These data support previously published evidence (20, 21) of T cell regulation of EBV-infeeted B cells.
Exact frequency analysis of responding cells will require limiting dilution analysis, which this system does not lend itself to yet. Thus, we have tried to find out the frequency of eternalizable cells by doing single cell transfer of EBNA-positive PFC to microwells with fibroblast feeder cells. One interpretation of these experiments is that either these eternalizable B cells are not recruited from the high-rate Ig-producing cells or else they appear in low frequency (<1/50).
Summary
Epstein-Barr virus (EBV) will infect at least every third cell if exposed in vitro to an extensively purified B cell population from human peripheral blood. About 10% of such infected cells will be driven into immunoglobulin synthesis and secretion, as judged by the indirect protein A plaque assay. The appearance of EB nuclear antigen, de novo DNA synthesis, and immunoglobulin secretion are linked phenomena accompanying infection as judged by viral dilution experiments, which yield kinetics of a one-hit order.
Induction of immunoglobulin secretion in B cells by EBV requires de novo synthesis of DNA, and consequently, nontransforming EBV (P3HR1) will not induce immunoglobulin secretion and will also specifically block such induction from subsequently added EBV.
The termination of immunoglobulin induction by EBV in short-term cultures appears to be T cell dependent.
